Next Article in Journal
Cytogenetic Study on the Biostimulation Potential of the Aqueous Fruit Extract of Hippophae rhamnoides for a Sustainable Agricultural Ecosystem
Next Article in Special Issue
Canthaxanthin, a Red-Hot Carotenoid: Applications, Synthesis, and Biosynthetic Evolution
Previous Article in Journal
Changes in the Phenolic Compounds of Hop (Humulus lupulus L.) Induced by Infection with Verticillium nonalfalfae, the Causal Agent of Hop Verticillium Wilt
Previous Article in Special Issue
Functional Improvement of Human Cardiotrophin 1 Produced in Tobacco Chloroplasts by Co-Expression with Plastid Thioredoxin m
Review

Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production

1
Research Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand
2
Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok 10330, Thailand
*
Author to whom correspondence should be addressed.
Plants 2020, 9(7), 842; https://doi.org/10.3390/plants9070842
Received: 1 May 2020 / Revised: 20 June 2020 / Accepted: 30 June 2020 / Published: 4 July 2020
(This article belongs to the Special Issue Plant Molecular Farming)
The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed. View Full-Text
Keywords: biopharmaceuticals; molecular farming; Nicotiana; plant production system; plant-derived protein; recombinant protein; transient expression biopharmaceuticals; molecular farming; Nicotiana; plant production system; plant-derived protein; recombinant protein; transient expression
Show Figures

Figure 1

MDPI and ACS Style

Shanmugaraj, B.; I. Bulaon, C.J.; Phoolcharoen, W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants 2020, 9, 842. https://doi.org/10.3390/plants9070842

AMA Style

Shanmugaraj B, I. Bulaon CJ, Phoolcharoen W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 2020; 9(7):842. https://doi.org/10.3390/plants9070842

Chicago/Turabian Style

Shanmugaraj, Balamurugan, Christine J. I. Bulaon, and Waranyoo Phoolcharoen. 2020. "Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production" Plants 9, no. 7: 842. https://doi.org/10.3390/plants9070842

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop